The FDA already conceded that LYTENAVA works. Now Outlook Therapeutics has roughly 60 days for a Class 1 resubmission decision — and a $100 million stock sitting on top of a multi-billion-dollar wet AMD market. Here is the actual setup, the three launch scenarios, and how to think about positioning.